Journal of Medical Economics
Volume 22, 2019 - Issue 4
Cardiovascular Medicine
Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis
Lisa Aniek de JongUnit of PharmacoTherapy, -Epidemiology & -Economics, University of Groningen, Groningen Research Institute of Pharmacy (GRIP), Groningen, the Netherlands; Correspondence[email protected]
http://orcid.org/0000-0001-8814-0670
http://orcid.org/0000-0001-8814-0670, , , & Maarten J. PostmaUnit of PharmacoTherapy, -Epidemiology & -Economics, University of Groningen, Groningen Research Institute of Pharmacy (GRIP), Groningen, the Netherlands; ;Institute for Science in Healthy Aging & healthcaRE (SHARE), University of Groningen, University Medical Center Groningen (UMCG), Groningen, the Netherlands; ;Department of Health Sciences, University of Groningen, University Medical Center Groningen (UMCG), the Netherlandshttp://orcid.org/0000-0002-6306-3653
http://orcid.org/0000-0002-6306-3653